대한신장학회

Skip Navigation: Skip to contents

KOR
ENG
전체메뉴보기

간행물 검색

현재 페이지 경로

HOME
간행물
간행물 검색

논문분류	춘계학술대회 초록집
제목	Lipid Hybrid Nanoparticles encapsulated VLPVPR: A potential therapeutic approach in Hypertension treatment.
저자	Kainat Alam, Sarwar Beg, Mahfoozur Rahman
출판정보	2020; 2020(1):
키워드	Antihypertensive peptide \| Hypertension \| lipid nanoparticles \| oral administration \| sustained release
초록	Drugs are administered orally during hypertension therapy. Antihypertensive peptides have outstanding efficacy in vitro to activate enzyme inhibitors. However, the poor oral bioavailability and therapeutic effects of antihypertensive peptides were mainly attributable to rapid gastrointestinal degradation and short blood circulation times to be further optimised. The new oral peptide delivery system is therefore urgently needed to improve the oral absorption and effectiveness of peptide drugs. In this work, the lipid hybrid nanoparticles loaded by Val-Leu-Pro-Val-Pro-Arg (VLPVPR) combines the advantages of lipid and polymer nanoparticles which could substantially improve oral bioavailability and sustained peptide release. Double-emulsion internal phase /organic/ external phase (W1/O/W2) solvent evaporation processes have been used for preparations of the VLPVPR loaded lipid polymer hybrid nanoparticles (VLPVPR-LPHNs). The optimum LPHNs for VLPVPR is 58.71 ± 3.8 nm, 5 ±0.85 mV for zeta potentials, high-capacity, 89±1.23%. Studies of electron microscopic propagation shows that core-shell lipid nanoparticles are spherical types that tend on the surface to contain a lipid bile layer. The VLPVPR progress in the VLPVPR- LPHNs was shown further by differential calorimetry screening. VLPVPR- LPHNs have been consistently released in vitro for an optimized preparation with 5 days of long-term in vivo antihypertensive benefit. Briefly, VLPVPR-LPHNs were successfully developed to treat hypertension using oral antihypertensive peptides.
원문(PDF)	PDF 원문보기

목록

위로가기